These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11365714)

  • 21. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
    Lisziewicz J; Jessen H; Finzi D; Siliciano RF; Lori F
    Lancet; 1998 Jul; 352(9123):199-200. PubMed ID: 9683211
    [No Abstract]   [Full Text] [Related]  

  • 22. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea for HIV?
    Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.
    Rutschmann OT; Vernazza PL; Bucher HC; Opravil M; Ledergerber B; Telenti A; Malinverni R; Bernasconi E; Fagard C; Leduc D; Perrin L; Hirschel B
    AIDS; 2000 Sep; 14(14):2145-51. PubMed ID: 11061656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
    Nokta M; Rossero R; Loesch K; Pollard RB
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
    Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
    J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
    Lori F
    AIDS; 1999 Aug; 13(12):1433-42. PubMed ID: 10465065
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
    Levin J
    AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles of treating HIV.
    Johnson D
    S Afr Med J; 2000 Mar; 90(3):227-30. PubMed ID: 10853393
    [No Abstract]   [Full Text] [Related]  

  • 35. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
    Lori F; Foli A; Groff A; Lova L; Whitman L; Bakare N; Pollard RB; Lisziewicz J
    AIDS; 2005 Jul; 19(11):1173-81. PubMed ID: 15990570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.